Role of Microorganisms in Drug Development: A Comprehensive Review
Abstract
Microorganisms play a pivotal role in various stages of drug development, contributing to the discovery, production, and testing of pharmaceuticals. It provides an extensive examination of the multifaceted interactions between microorganisms and drug development processes. From natural product discovery to fermentation-based production and microbiome research, microorganisms influence drug development significantly. Understanding these microbial contributions is crucial for advancing drug development strategies and fostering innovation
in the pharmaceutical industry.
How to cite this article:
Kshitij K, Tyagi A, khuswah A. Role of
Microorganisms in Drug Development: A
Comprehensive Review. J Durg Dis Dev 2023;
7(2): 27-31.
References
Brown ED, Wright GD. Antibacterial resistance: the good, the bad, and the ugly. Trends in Microbiology. 2016;24(6): 413-415.
Lewis K. Platforms for antibiotic discovery. Nature Reviews Drug Discovery. 2013;12(5): 371-387.
Walsh C. Where will new antibiotics come from? Nature Reviews Microbiology. 2003;1(1): 65-70.
Wright GD. Antibiotic adjuvants: rescuing antibiotics from resistance. Trends in Microbiology. 2016;24(11): 862-871.
Davies J, Davies D. Origins and evolution of antibiotic resistance. Microbiology and Molecular Biology Reviews. 2010;74(3): 417-433.
Clardy J, Fischbach MA, Walsh CT. New antibiotics from bacterial natural products. Nature Biotechnology. 2006;24(12): 1541-1550.
Butler MS, Blaskovich MA, Cooper MA. Antibiotics in the clinical pipeline at the end of 2015. The Journal of Antibiotics. 2017;70(1): 3-24.
Piddock LJ. Reflecting on the final report of the O’Neill Review on Antimicrobial Resistance. The Lancet Infectious Diseases. 2016;16(7): 767-768.
Projan SJ. Why is big Pharma getting out of antibacterial drug discovery? Current Opinion in Microbiology. 2003;6(5): 427-430.
Berdy J. Thoughts and facts about antibiotics: where we are now and where we are heading. Journal of Antibiotics. 2012;65(8): 385-395.
Demain AL, Sanchez S. Microbial drug discovery: 80 years of progress. The Journal of Antibiotics. 2009;62(1): 5-16.
Challis GL. Genome mining for novel natural product discovery. Journal of Medicinal Chemistry. 2008;51(9): 2618-2628.
Genilloud O. Actinomycetes: still a source of novel antibiotics. Nature Reviews Microbiology. 2017;15(7): 401-413.
Walsh CT, Wencewicz TA. Prospects for new antibiotics: a molecule-centered perspective. Journal of Antibiotics. 2014;67(1): 7-22.
Ventola CL. The antibiotic resistance crisis: part 1: causes and threats. Pharmacy and Therapeutics. 2015;40(4): 277-283.
Ling LL, Schneider T, Peoples AJ, Spoering AL, Engels I, Conlon BP, et al. A new antibiotic kills pathogens without detectable resistance. Nature. 2015;517(7535): 455-459.
Wright GD. The antibiotic resistome: the nexus of chemical and genetic diversity. Nature Reviews Microbiology. 2007;5(3): 175-186.
Fischbach MA, Walsh CT. Antibiotics for emerging pathogens. Science. 2009;325(5944): 1089-1093.
Downloads
Published
How to Cite
Issue
Section
License
Copyright (c) 2023 Author'sWe, the undersigned, give an undertaking to the following effect with regard to our article entitled
“_______________________________________________________________________________________________________________________________________________________________________________
________________________________________________________________________________” submitted for publication in (Journal title)________________________________________________ _______________________________________________________Vol.________, Year _________:-
1. The article mentioned above has not been published or submitted to or accepted for publication in any form, in any other journal.
2. We also vouchsafe that the authorship of this article will not be contested by anyone whose name(s) is/are not listed by us here.
3. I/We declare that I/We contributed significantly towards the research study i.e., (a) conception, design and/or analysis and interpretation of data and to (b) drafting the article or revising it critically for important intellectual content and on (c) final approval of the version to be published.
4. I/We hereby acknowledge ADRs conflict of interest policy requirement to scrupulously avoid direct and indirect conflicts of interest and, accordingly, hereby agree to promptly inform the editor or editor's designee of any business, commercial, or other proprietary support, relationships, or interests that I/We may have which relate directly or indirectly to the subject of the work.
5. I/We also agree to the authorship of the article in the following sequence:-
Authors' Names (in sequence) Signature of Authors
1. _____________________________________ _____________________________________
2. _____________________________________ _____________________________________
3. _____________________________________ _____________________________________
4. _____________________________________ _____________________________________
5. _____________________________________ _____________________________________
6. _____________________________________ _____________________________________
7. _____________________________________ _____________________________________
8. _____________________________________ _____________________________________
Important
(I). All the authors are required to sign independently in this form in the sequence given above. In case an author has left the institution/ country and whose whereabouts are not known, the senior author may sign on his/ her behalf taking the responsibility.
(ii). No addition/ deletion/ or any change in the sequence of the authorship will be permissible at a later stage, without valid reasons and permission of the Editor.
(iii). If the authorship is contested at any stage, the article will be either returned or will not be
processed for publication till the issue is solved.
